The acquisition of Gentronix by Scantox marks a significant development in the life sciences sector.
- Gentronix is renowned for offering high-quality genetic toxicology solutions, beneficial to the pharmaceutical, biotech, and agrichemical industries.
- The acquisition enables Scantox to fill a gap in its portfolio, aiming to become a comprehensive CRO partner.
- Gentronix’s leadership sees potential in Scantox’s backing, promising enhanced service portfolios for clients.
- Originally supported by Mercia Ventures, Gentronix now transitions to a promising new phase with Scantox.
The acquisition of Gentronix, a rapidly expanding life sciences company based in Alderley Park, by the Danish enterprise Scantox Group signifies a pivotal juncture for both entities. Founded in 1999 by Professor Richard Walmsley, Gentronix has long been acknowledged for its expertise in genetic toxicology, catering to sectors including pharmaceuticals, biotechnology, and agrichemicals.
Over the past five years, Gentronix has undergone substantial growth, a feat recognised by Scantox, which aims to integrate Gentronix’s services into its offerings. This strategic move is seen as a ‘fantastic next step’ by Gentronix’s leadership team, which consists of 70 proficient staff members committed to advancing the company’s legacy and market influence.
Under the terms of the acquisition, Mercia Ventures’ Northern Venture Capital Trusts successfully divested their stake in Gentronix for £14.8 million, yielding a 4.5x return on investment. This transition emblematises the culmination of sustained growth and development under the stewardship of Gentronix’s existing management, paving the way for new opportunities under Scantox’s ownership.
Scantox, headquartered in Ejby near Copenhagen, regards this acquisition as an opportunity to enhance its service capacity, specifically in genetic toxicology – an area frequently demanded by their clientele. Jeanet Løgsted, CEO of Scantox, noted the complementary nature of Gentronix’s services, underscoring the strategic advantage and alignment in corporate culture and operational ethos.
The integration of Gentronix into Scantox is also set to nurture commercial synergy, enabling the expansion of Scantox’s service portfolio. This enlargement is aligned with Scantox’s ambition to uphold scientific excellence and serve a more extensive global clientele with enhanced research services.
Nicholas Hooge of Impilo echoed this sentiment, highlighting the substantial growth prospects envisaged for the amalgamated entity. Meanwhile, Alex Gwyther of Mercia Ventures lauded the role of patient capital in fostering Gentronix’s evolution, stating that its merger with Scantox is well-timed and strategically advantageous.
The collaboration between Gentronix and Scantox promises to form a leading global force in toxicology and pharmaceutical development.
